Article

Cardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort Study

2026-08-06

Abstract excerpt

<title>Abstract</title> <p> <bold>Background/Objectives:</bold> Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves greater weight loss than semaglutide in adults with obesity without type 2 diabetes (T2D), but no randomised trial has directly compared their cardiovascular outcomes in this population. We compared major adverse cardiovascular events (MACE) and other cardiorenal outcomes between the two agen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b3532d9f-d881-5075-bb3d-68ee332ba4da
DOI: 10.21203/rs.3.rs-9855917/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort StudyDOI 10.21203/rs.3.rs-9855917/v1Read

Cardiorenal outcomes of tirzepatide versus semaglutide in adults with type 2 diabetes and chronic kidney disease: a target trial emulation in the TriNetX Global Collaborative NetworkSemantic proximity Read

Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudySemantic proximity Read

Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysisSemantic proximity Read

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort studySemantic proximity Read

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity Read

Cardiovascular Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes or Obesity Undergoing Surgical Aortic Valve ReplacementSemantic proximity Read

Effect of SGLT-2 Inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Controlled TrialsSemantic proximity Read

Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis.Semantic proximity Read

Ambulatory BP and Weight Reduction as Predictors of GLP-1RA CV BenefitSemantic proximity Read

Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes: An Umbrella ReviewSemantic proximity Read

Tirzepatide and potential use for metabolically healthy obesity.Semantic proximity Read

Current status of anti-obesity medications and performance, an EHR based surveySemantic proximity Read